Litcius/Paper detail

Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab

Vibeke Strand, Sean O’Quinn, Richard Furie, Eric F. Morand, Kenneth Kalunian, Erik Schwetje, Gabriel Abreu, Raj Tummala

2022The Lancet Rheumatology16 citationsDOI

Topics & Concepts

MedicineSystemic lupus erythematosusPost-hoc analysisPlaceboQuality of life (healthcare)Internal medicineClinical trialLupus erythematosusPhysical therapyDiseaseImmunologyAlternative medicineAntibodyPathologyNursingSystemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and Treatments
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab | Litcius